Deutsche Bank
AVTX icon

Deutsche Bank’s Avalo Therapeutics AVTX Stock Holding History

Deutsche Bank’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.24M Hold
150,000
– – ﹤0.01% 1713
2025
Q4 		$2.72M Buy
+150,000
New +$2.53M ﹤0.01% 1627
2022
Q2 		– Sell
-39
Closed -$82K – 4130
2022
Q1 		$82K Buy
39
+25
+179% +$62.8K ﹤0.01% 3649
2021
Q4 		$66K Buy
14
+3
+27% +$18K ﹤0.01% 3870
2021
Q3 		$69K Hold
11
– – ﹤0.01% 4027
2021
Q2 		$107K Buy
11
+2
+22% +$16.8K ﹤0.01% 4113
2021
Q1 		$74K Hold
9
– – ﹤0.01% 4118
2020
Q4 		$71K Buy
9
+2
+29% +$13.9K ﹤0.01% 4009
2020
Q3 		$44K Buy
7
+2
+40% +$15K ﹤0.01% 3938
2020
Q2 		$38K Sell
5
-2
-29% -$14.5K ﹤0.01% 3923
2020
Q1 		$50K Hold
7
– – ﹤0.01% 3544
2019
Q4 		$110K Buy
7
+5
+250% +$52.7K ﹤0.01% 3540
2019
Q3 		$21K Sell
2
-2
-50% -$22.3K ﹤0.01% 4298
2019
Q2 		$58K Buy
+4
New +$60.6K ﹤0.01% 4454
2018
Q4 		– Sell
-1
Closed -$14K – 5150
2018
Q3 		$14K Buy
+1
New +$13.1K ﹤0.01% 5010
2018
Q2 		– Hold
0
– -$1K – 5400
2018
Q1 		– Hold
0
– – – 5329
2016
Q4 		– Hold
0
– – – 4903
2016
Q3 		– Hold
0
– – – 4903
2016
Q2 		– Hold
0
– – – 5166
2016
Q1 		– Hold
0
– – – 5141

Other funds holding AVTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Deutsche Bank's AVTX Position: Q1 2026 in Review

Deutsche Bank held its Avalo Therapeutics (AVTX) position steady in Q1 2026 at 150,000 shares worth $2.24M. The position accounts for ﹤0.01% of the portfolio, ranked #1713.

Deutsche Bank first reported a position in AVTX in Q3 2018 and has held it in 15 quarters since. The position peaked at $2.72M in Q4 2025. 97 funds tracked by Wall St. Rank hold AVTX as of Q1 2026.

  • Deutsche Bank held 150,000 shares of Avalo Therapeutics worth $2.24M as of Q1 2026.
  • Deutsche Bank left its Avalo Therapeutics share count unchanged in Q1 2026.
  • Avalo Therapeutics made up ﹤0.01% of Deutsche Bank's portfolio in Q1 2026, its #1713 holding.
  • Deutsche Bank first reported a position in Avalo Therapeutics in Q3 2018 and has held it in 15 quarters since.
  • Deutsche Bank's Avalo Therapeutics position peaked at $2.72M in Q4 2025.
  • 97 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q1 2026.

Based on Deutsche Bank's 13F filing for Q1 2026, filed 6 May 2026.